GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (STU:ISI) » Definitions » PB Ratio

Ionis Pharmaceuticals (STU:ISI) PB Ratio : 19.18 (As of May. 14, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-14), Ionis Pharmaceuticals's share price is €35.86. Ionis Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was €1.87. Hence, Ionis Pharmaceuticals's PB Ratio of today is 19.18.

The historical rank and industry rank for Ionis Pharmaceuticals's PB Ratio or its related term are showing as below:

STU:ISI' s PB Ratio Range Over the Past 10 Years
Min: 4.16   Med: 11.08   Max: 66.79
Current: 19.09

During the past 13 years, Ionis Pharmaceuticals's highest PB Ratio was 66.79. The lowest was 4.16. And the median was 11.08.

STU:ISI's PB Ratio is ranked worse than
95.05% of 1312 companies
in the Biotechnology industry
Industry Median: 2.48 vs STU:ISI: 19.09

During the past 12 months, Ionis Pharmaceuticals's average Book Value Per Share Growth Rate was -40.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -20.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -20.50% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 9.90% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Ionis Pharmaceuticals was 526.60% per year. The lowest was -75.70% per year. And the median was -2.30% per year.

Back to Basics: PB Ratio


Ionis Pharmaceuticals PB Ratio Historical Data

The historical data trend for Ionis Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals PB Ratio Chart

Ionis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.72 10.66 5.57 9.11 18.54

Ionis Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.33 13.65 21.17 18.54 21.76

Competitive Comparison of Ionis Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Ionis Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's PB Ratio falls into.



Ionis Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Ionis Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=35.86/1.87
=19.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Ionis Pharmaceuticals  (STU:ISI) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Ionis Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ionis Pharmaceuticals (STU:ISI) Business Description

Traded in Other Exchanges
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals (STU:ISI) Headlines

No Headlines